Healthcare & Health Industry Wire — Week of September 22, 2026: A Medicare lab-price reset, a $600 million benefits raise, and a 5-2 merger vote
This week's U.S. healthcare scan covers Angle Health's $600 million raise for small-employer coverage, the first drug approved for the movement disorder of ataxia-telangiectasia, Medicare's plan to pay labs closer to private rates, a 5-2 vote advancing the Atrium-WakeMed merger, and how to check a fat-dissolving injection.
Coverage window: September 15-22, 2026
This edition covers U.S. healthcare developments published or completed during September 15-22, 2026. A benefits startup for small employers raised the week's largest private round. The U.S. Food and Drug Administration (FDA) settled three drug questions and one software question. Medicare published the preliminary laboratory prices it intends to pay from January. And the largest hospital combination on the table in North Carolina cleared its first political test.
1. Health-tech funding and products
Angle Health raises $600 million to sell coverage to small employers
Status: Angle Health announced the financing on September 18; the round was still open and expected to close later in September.
Angle Health raised $600 million in equity at a valuation of $2.7 billion. The package has two parts: a $200 million Series C round led by Vitruvian Partners, and a $400 million tender offer that buys shares from existing holders. Town Hall Ventures joined as a new investor, with Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator returning. 1
Angle Health sells health coverage to small and mid-sized employers and runs the plan on its own software, which combines medical and pharmacy claims, demographic data and population health data so an employer can see where its spending is going. The new valuation is more than double the one attached to the company's December 2025 Series B round of $134 million; it raised $58 million in January 2023. 1
Angle Health says it serves more than 5,000 employers in 47 states, carries close to $1 billion in annualized premium-equivalents and grew 120% year over year. Those are company figures. An employer weighing the platform against a traditional carrier needs to know whether its network and care navigation hold down claims, and no independent comparison of that is public. 1
Loading stats card…
Zocdoc opens its booking network to payers and platforms
Status: Zocdoc announced the enterprise offering, Care Access Network, on September 17.
Zocdoc will license the appointment-booking system behind its consumer marketplace so payers and technology or consumer platforms can embed booking in their own sites and apps. The marketplace connects to more than 200,000 providers across more than 200 specialties and 10,000 insurance plans. Amazon Health AI is a launch partner, and Google's Gemini, Yelp, Healthgrades, Blue Shield of California and WellHive are also connecting. 2
For a patient, the change is where a search ends. Someone who asks Gemini to book a visit for a specific problem gets a Zocdoc widget with open slots and finishes the booking inside Zocdoc's interface. Blue Shield of California, which began working with Zocdoc in 2025, reports 2 million hours of bookable appointments in a 90-day period, a sevenfold increase in booked appointments and an average wait of six days. Those results come from the plan and the company. 2
Oura and Counsel Health take wearables into Medicare's chronic-care model
Status: Counsel Health and Oura disclosed their participation in the ACCESS Model on September 17.
Counsel Health, an AI-native primary care company, will join the Centers for Medicare & Medicaid Services (CMS) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model under its early cardio-kidney-metabolic track, with Oura's smart ring as the preferred wearable. From early 2027, Counsel plans to offer chronic care management at no cost to Medicare beneficiaries with hypertension, obesity, hyperlipidemia or prediabetes, and Oura users will be able to enroll through the ring's app. 3
Oura reports five million paid members, most of whom wear the ring about 23.5 hours a day. In the first nine weeks of the partnership, the two companies say, 36,000 Oura members finished onboarding to Counsel's services, and members who saw a physician rated the experience 4.6 out of 5. Those results are company-reported and cover a young partnership. 3
2. Pharma and device FDA news
The FDA approves the first drug for the movement disorder of ataxia-telangiectasia
Status: The FDA announced the approval of Aqneursa on September 18; the same drug has been approved since 2024 for a different rare disease.
Aqneursa (levacetylleucine) is an oral suspension for ataxia in adults and children with ataxia-telangiectasia who weigh at least 15 kilograms (about 33 pounds), and it is the first treatment approved for that symptom of the disease. Ataxia-telangiectasia is an inherited disorder caused by mutations in the ATM gene. It erodes coordination from early childhood and also brings dilated blood vessels, immune deficiency and a heightened risk of cancer. 4
The evidence comes from a crossover trial of 73 patients aged 4 and older: 26 adults and 47 children, with a median age of 13, randomly assigned to take the drug and then a placebo, or the placebo and then the drug, in 12-week periods. Seventy of them finished. The trial scored gait, sitting, stance and speech on a 16-point scale, and patients scored better while taking Aqneursa than while taking the placebo. The most common side effects were falls, skin lacerations and urinary tract infections, and the drug may cause fetal harm. Approval went to IntraBio. 4
A two-drug combination for a mutation-defined breast cancer
Status: The FDA approved imlunestrant with abemaciclib on September 18, and cleared a blood test for selecting patients the same day.
Imlunestrant, sold as Inluriyo, and abemaciclib, sold as Verzenio and already widely used, treat adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. Both drugs are made by Eli Lilly, and the Guardant360 CDx blood test, which detects the ESR1 mutation, is the companion diagnostic. 5
The 874-patient EMBER-3 trial tested the pair against imlunestrant alone and against a choice of two standard endocrine therapies. Among the 159 patients whose tumors carried an ESR1 mutation, median progression-free survival was 11.1 months on the combination and 5.5 months on imlunestrant alone, and 35% versus 15% of patients responded. The FDA also reports that imlunestrant by itself did not beat the standard endocrine therapies, so the measured benefit belongs to the two drugs given together. The recommended doses are 400 milligrams of imlunestrant once a day on an empty stomach and 150 milligrams of abemaciclib twice a day. 5
A Medtronic esophageal test is recalled after 184 serious injuries
Status: The FDA classified the recall as Class I, its most serious category, on September 15.
Medtronic and its subsidiary Given Imaging told customers to stop using two Bravo CF capsule delivery devices, product numbers FGS-0635 and FGS-0636, covering every lot that expires on or before October 20, 2027. The capsule may fail to attach to the esophagus or fail to detach from the delivery device, a problem the company traces to the component that controls deployment. The listed risks include aspiration, perforation of the esophagus, obstruction of the airway, bleeding, a delay in diagnosis and foreign bodies left in the patient. Medtronic reported 184 serious injuries and no deaths as of August 10. 6
Hospitals and clinics holding the devices should quarantine them and return them to Medtronic for replacement. Lots expiring December 10, 2027 or later sit outside the recall. 6
The FDA turns down a request to skip premarket review for AI radiology software
Status: The FDA's order settling the petition took effect September 17.
Harrison.ai asked the FDA in October 2025 to exempt four kinds of radiology artificial intelligence devices from 510(k) premarket notification — software that flags lesions suspicious of cancer, medical image analyzers, triage and notification software, and computer-aided detection and diagnosis software — for manufacturers that already held a clearance of the same kind and met the petition's post-market commitments. The FDA published the petition for comment in December 2025 and denied it on April 1, 2026, after concluding the petition did not show that premarket review is unnecessary to assure the safety and effectiveness of those devices. The September 17 order makes the denial final, so manufacturers of these devices must keep submitting and clearing a 510(k) before they market them. 7
Loading stats card…
The FDA also added a warning to the label of Kybella (deoxycholic acid) injection on September 15 about reactions that follow injections outside the area under the chin. Section 5 covers what that change means for anyone considering the procedure. 8
3. Insurance and policy
Medicare moves to pay clinical labs closer to private rates
Status: CMS released the preliminary 2027 rates on September 21; the rates would take effect January 1, 2027.
The agency says Medicare has been paying about 16% more than private payers for laboratory services, and that aligning the two would save an estimated $1 billion a year. The data behind the preliminary 2027 Clinical Laboratory Fee Schedule comes from laboratories, gathered under a process Congress created in 2014 that has been used once since; the Consolidated Appropriations Act, 2026 lets CMS collect updated private-payer data every three years. 9
Two limits govern how fast that happens. Payment for a clinical diagnostic laboratory test cannot fall more than 15% a year through 2029, so CMS phases the reductions in over several years. And for tests that drew no private-payer data, CMS held a public meeting on September 15 and 16 to decide on prices, with those determinations due in early October and their own 30-day comment period. Comments on the preliminary rates are open for 30 days, and CMS expects to finalize the rates in November 2026. 9
All 50 states line up for Medicaid's most-favored-nation drug model
Status: CMS announced the participant list on September 18; states have until September 30 to sign agreements.
All 50 states, the District of Columbia and Puerto Rico applied to the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, and 40 states plus Puerto Rico have signed. Under the model, participating drugmakers make covered outpatient drugs available to participating state Medicaid programs at the prices other countries pay, and states invoice the manufacturers for supplemental rebates. CMS monitors pricing accuracy and shares in the rebates by reducing the federal share of Medicaid payments. CMS projects $64.3 billion in savings to taxpayers over ten years. The model began in January 2026 and runs five years. 10
Medicare's technology-supported chronic care model adds five conditions
Status: CMS announced the expansion of the ACCESS Model on September 15; the new tracks start in spring 2027.
Medicare's ACCESS Model pays participating organizations for measurable gains in a patient's health rather than for individual services, and lets them deliver virtual care, health coaching, remote monitoring and connected devices between doctor visits. CMS added five tracks: heart failure, chronic obstructive pulmonary disease, substance use disorders, tobacco cessation, and continued support for bone, joint and mobility conditions past the first 12 months. The model already covers high blood pressure, diabetes, chronic musculoskeletal pain and depression. 11
One hundred sixty organizations now take part, out of a model that runs ten years, and CMS maintains a directory at Medicare.gov/ACCESS. Participation is voluntary, does not change a beneficiary's benefits or provider choice, and is open to people in Original Medicare; Medicare Advantage enrollees are outside the model, though their plans may run similar programs. CMS says three of every four people with Medicare qualify for at least one ACCESS track. 11
Four more states receive rural health transformation awards
The Rural Health Transformation Program (RHTP) is the $50 billion program created by the Working Families Tax Cuts Act, and it distributes money to states for rural care. Four awards landed this week.
- South Carolina, $167 million: 228 grants for pop-up care locations, mobile vans, new clinics, school-based mental health services, electronic health records, remote monitoring, cybersecurity upgrades at a rural hospital and a specialized obstetrical surgical robot. 12
- Mississippi, more than $104 million: 167 grants, split into about $47.4 million for 97 technology and cybersecurity projects, nearly $43.3 million for 43 projects closing gaps in surgical, specialty, diagnostic, maternal and behavioral care, and nearly $13.4 million for 27 telehealth projects. 13
- Connecticut, $50 million: money for four rural hospital systems to upgrade equipment, renovate facilities and restructure service lines, on top of more than $7 million the state received earlier for prevention work. 14
- New Mexico, $74 million: funding for six regional hub organizations under the state's Healthy Horizons plan, which coordinates specialty, maternal, behavioral health and chronic disease services for rural, frontier and tribal communities. 15
Loading stats card…
4. Hospital M&A
Wake County commissioners clear the Atrium-WakeMed combination
Status: The Wake County Board of Commissioners voted 5-2 on September 21 to approve the proposed combination; regulatory review comes next.
The vote covers the plan WakeMed Health & Hospitals of Raleigh and Atrium Health of Charlotte set out in early May: a single system, with $2 billion from Atrium invested in WakeMed facilities, technology, workforce and access, and a $150 million Wake County Whole Health Program aimed at needs outside hospitals and physician offices. The amended transfer agreement raises the minimum threshold for charity care and adds assurances about access regardless of ability to pay. 16
County leaders and state officials have raised questions about competition, governance and cost through the review, and WakeMed turned down an unsolicited partnership proposal from UNC Health in May. Atrium, part of Charlotte-based Advocate Health, runs 19 hospitals and more than 1,060 care locations across North Carolina. WakeMed is a nonprofit with three full-service hospitals, a mental health hospital, eight emergency departments, two trauma centers, more than 12,800 employees and 1,300 affiliated physicians. 16
Regulatory review is the next gate, and the definitive agreements are where the terms behind the charity-care commitment — how that minimum is calculated and enforced — will appear.
Other transactions that moved this week
- NYC Health + Hospitals and Maimonides Health: New York State's Public Health and Health Planning Council approved the proposal unanimously on September 17 for Maimonides, which runs three hospitals and dozens of community sites, to join the city's public health system. Maimonides would receive more than $2.2 billion in state grant funding over five years, including more than $500 million for an electronic health record, labor and delivery space and other capital work. Final state approvals are expected in the fall. 17
- Intermountain Health and Surgery Partners: Intermountain closed on majority ownership of Idaho Falls Community Hospital and Mountain View Hospital on September 17 by acquiring Surgery Partners' stake. Surgery Partners received $797 million in gross proceeds and $587 million in net cash, and Medical Properties Trust separately sold the hospitals' real estate to Intermountain affiliates for $413 million, netting $371 million. The two hospitals have 126 beds, employ more than 150 physicians and keep their brands and local management. 18
- Insight Health Systems and Ramco Healthcare Holdings: Ramco settled with the operator Resilience Healthcare on September 16 and took over Weiss Memorial Hospital in Chicago and West Suburban Medical Center in Oak Park, Ill. the next day, with a plan to pass both to Flint, Mich.-based Insight Health Systems. Earlier court filings put that sale at $1. Weiss Memorial closed in August 2025, and West Suburban shut down in June after its last working elevator failed; Illinois had declined to extend Weiss Memorial's provisional license. Insight's hospital division chief executive called the takeover "the start of a long, phased process," with licences and certifications still to be restored. 19
- Carle Health: Carle Health Methodist and Proctor hospitals in Peoria, Ill. will operate as one hospital with two campuses from November 1, with Proctor renamed Carle Health Methodist Hospital – Proctor Campus, the Urbana, Ill.-based system announced September 18. Care continues at both sites, and the system reports no staff impact. 20
5. Patient health tip: check the product and the injector before a fat-dissolving shot
Action: Before any injected fat treatment, confirm the product is FDA-approved for the area being treated and that a licensed health care professional is giving it, and never buy the drug online to inject yourself.
The FDA's September 15 action on Kybella (deoxycholic acid) injection turned on what happens when the drug is used away from its approved site. Kybella was approved in 2015 to improve the appearance of moderate to severe fullness under the chin, and it is not approved for fat anywhere else on the body. Among 129 reports the agency reviewed, patients who received deoxycholic acid injections outside the chin area suffered blurred or reduced vision, involuntary eye contractions, muscle and nerve damage, numbness and difficulty walking. The agency now recommends against that use. 8
The same review added another risk that applies to approved use. The FDA identified 117 reports of nodules 3 centimeters or smaller, or masses larger than that, at injection sites, some still present months later: the unresolved ones had lasted a mean of 143 days, or roughly five months, and may need medical treatment. The most common reactions already in the label include nerve injury around the lower lip, tongue and jaw, difficulty swallowing, bruising, tissue damage and infection at the injection site. 8
The FDA's guidance for patients covers the rest of what can be checked in advance. Only health care providers should administer the injection, and the label allows up to six treatments, each at least a month apart, of up to 50 injections through a single treatment. Unapproved fat-dissolving products are sold online under names including Aqualyx, Lipodissolve, Lipo Lab and Kabelline, and the agency has received reports of permanent scars, serious infections, skin deformities and painful knots from them, including cases where the injections were given at clinics or med spas by staff who may not have been licensed to inject. Patients should tell a regular clinician about any cosmetic injection they have received, and report a bad reaction to the FDA's MedWatch program. 21
Bottom line
Each item carries its own next milestone. Angle Health's round funds platform work and hiring, and any effect on what a small employer is quoted will show up in its plan designs, which the company has not published. The FDA moved one rare-disease treatment closer to patients in a disease with no other option, restricted where a cosmetic injection may be used, and left AI radiology software under premarket review. Medicare's lab-price comment period runs 30 days, with final rates expected in November and in effect from January 1; states have until September 30 to join the Medicaid drug model; and the new ACCESS tracks open in spring 2027. The Atrium-WakeMed combination moves to regulatory review, while three other hospital deals closed or changed hands. For a patient weighing an injected fat treatment, the questions worth settling before the appointment are what the product is and who is holding the syringe.
References
- 1Angle Health snags $600M, hits $2.7B valuation
fiercehealthcare.com
- 2Zocdoc's enterprise offering powers bookings anywhere
fiercehealthcare.com
- 3Counsel Health taps Oura to join CMS ACCESS model
fiercehealthcare.com
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16WakeMed, Atrium merger clears major hurdle
beckershospitalreview.com
- 17NYC Health + Hospitals, Maimonides Health deal clears state council
beckershospitalreview.com
- 18Intermountain completes acquisition of 2 Idaho hospitals
beckershospitalreview.com
- 19Insight to take over 2 closed Illinois hospitals
beckershospitalreview.com
- 20Carle Health to unite 2 hospitals
beckershospitalreview.com
- 21
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.